Product Description
Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607051.html)
Mechanisms of Action: TK Inhibitor,VEGFR Inhibitor,RAFk Inhibitor,PGFR Inhibitor,Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Costa Rica, Croatia, Czech Republic, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Malaysia, New Zealand, Philippines, Poland, Puerto Rico, Romania, Russia, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 27
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Liver Cancer
Phase 2: Colorectal Cancer|Hepatitis A|Hepatitis B|Hepatitis C|Kidney Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| WGI0301-P2G-01 | P2 |
Not yet recruiting |
Hepatocellular Carcinoma |
2026-08-01 |
|
| jRCT2031210045 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2026-03-31 |
|
| ALIVE | P3 |
Recruiting |
Hepatocellular Carcinoma |
2025-08-01 |
|
| IMbrave251 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2025-07-09 |